-
11.发明公开
公开(公告)号：EP4424302A1
公开(公告)日：2024-09-04
申请号：EP22903257.8
申请日：2022-11-29
发明人： DONG, Qing , XUE, Lubing , TANG, Xin
IPC分类号： A61K9/10 , A61K31/404 , A61K31/44 , A61K45/00 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/44 , A61P9/10 , A61P27/02 , A61P27/06
CPC分类号： A61P3/10 , A61K47/44 , A61K47/10 , A61K31/404 , A61K9/10 , A61P9/10 , A61K47/34 , A61K45/00 , A61K31/44 , A61K9/08 , A61P27/10 , A61K47/36 , A61K47/38 , A61P27/02 , A61P27/06
摘要： An ophthalmic preparation of a tyrosine kinase inhibitor suitable for eye drop administration is prepared from the following active ingredients and adjuvants in parts by weight: active ingredient: 0.5-1.5 parts of tyrosine kinase inhibitor, wherein the content of the active ingredient in the ophthalmic preparation is 0.1-1 mg/mL; and pharmaceutically acceptable adjuvants: 200-300 parts of the surfactant, 0.5-7.0 parts of the tackifier, 10-800 parts of the solubilizer, with the balance being solvent. The ophthalmic preparation can effectively deliver the active ingredient to the fundus oculi to treat fundus angiogenesis diseases, with high absorption and utilization rate, small particle size and good stability, which are suitable for preparing sterile preparation by means of microporous filter membrane sterilization method and/or high-temperature sterilization method.
-
公开(公告)号：EP4417684A1
公开(公告)日：2024-08-21
申请号：EP22881009.9
申请日：2022-10-11
申请人： AJINOMOTO CO., INC.
IPC分类号： C12N1/21 , A61K35/74 , A61K35/742 , A61K35/744 , A61K35/745 , A61K35/747 , A61P1/00 , A61P1/02 , A61P3/04 , A61P9/10 , A61P17/00 , A61P17/02 , A61P35/00 , C12N15/12 , C12P1/04 , C12P21/02
CPC分类号： A61K35/74 , A61K35/742 , A61K35/744 , A61K35/745 , A61K35/747 , A61P1/00 , A61P1/02 , A61P3/04 , A61P9/10 , A61P17/00 , A61P17/02 , A61P35/00 , C07K14/435 , C12N15/74 , C12P1/04 , C12P21/02
摘要： Provided is a technology whereby a heterologous protein can be expressed in a bacterium which does not have an endogenous Tat system secretion machine. The present specification discloses a bacterium that is selected from the group consisting of bifidobacteria, lactococci, and staphylococci and has been modified to express a heterologous Tat protein. The bacterium has the ability to produce and secrete a heterologous protein.
-
公开(公告)号：EP4417611A1
公开(公告)日：2024-08-21
申请号：EP22880413.4
申请日：2022-10-14
发明人： CHEN, Liang , SHAN, Yuefeng , YANG, Xinye , WANG, Xiaojun
IPC分类号： C07D491/044 , A61K31/4353 , A61K31/42 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/12 , A61P3/00 , A61P3/06 , A61P3/10 , A61P35/00 , A61P1/00 , A61P1/04 , A61P1/16 , A61P31/04 , A61P31/20
CPC分类号： A61K31/42 , A61K31/4353 , A61K31/438 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/00 , A61P3/04 , A61P3/06 , A61P3/10 , A61P7/02 , A61P9/10 , A61P9/12 , A61P9/00 , A61P9/04 , A61P25/00 , A61P29/00 , A61P31/04 , A61P25/32 , A61P35/00 , A61P31/20 , C07D491/044 , C07D491/107
摘要： A new crystal form of a nitrogen-containing tricyclic compound and a use thereof, relating to a new crystal form of 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-10H-spiro[benzo[6,7]oxepino[3,2-b]pyridine-11,1'-cyclopropane]-7-carboxylic acid, the new crystal form being a crystal form H, and also relating to a pharmaceutical composition comprising the crystal form H, and a use of the crystal form H or the pharmaceutical composition in the preparation of a drug for preventing, treating or alleviating diseases mediated by FXR in patients.
-
公开(公告)号：EP4417609A1
公开(公告)日：2024-08-21
申请号：EP22880404.3
申请日：2022-10-14
发明人： YANG, Xinye , SHAN, Yuefeng , CHEN, Liang , WANG, Xiaojun
IPC分类号： C07D491/044 , A61K31/4353 , A61P9/10 , A61P9/12 , A61P9/04 , A61P9/00 , A61P15/10 , A61P3/00 , A61P35/00 , A61P29/00 , A61P1/16 , A61P3/10 , A61P7/02 , A61P7/06 , A61P31/20 , A61P1/00
CPC分类号： A61K31/4353 , A61K31/438 , A61P1/00 , A61P1/16 , A61P3/00 , A61P3/06 , A61P3/10 , A61P5/50 , A61P7/02 , A61P7/06 , A61P9/10 , A61P9/12 , A61P9/00 , A61P9/04 , A61P15/10 , A61P25/00 , A61P29/00 , A61P27/02 , A61P35/00 , A61P31/20 , C07D491/044 , C07D491/107
摘要： Provided are a new crystal form and use of a nitrogenous tricyclic compound in the field of drugs. Specifically, the present invention relates to a new crystal form of 2-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-10/7-spiro[benzo[6,7]oxepino[3,2-b]pyridine-11,1'-cyclopropane]-7-carboxylic acid, and the new crystal form is a crystal form I. The present invention further relates to a pharmaceutical composition comprising the crystal form I, and the use of the crystal form I or the pharmaceutical composition in preparation of a drug for preventing, treating, or relieving an FXR-mediated disease of a patient.
-
公开(公告)号：EP4410301A1
公开(公告)日：2024-08-07
申请号：EP21958636.9
申请日：2021-09-28
发明人： QUAN, Junmin , YANG, Zhen , LIU, Siyu , ZHANG, Qingzhou , HU, Minqiang , LI, Fengxia , FU, Jiamiao , ZHU, Zhendong , LI, Qinkai
摘要： The present invention belongs to the technical field of biomedicine, and specifically relates to an extracellular cyclophilin inhibitor and the use thereof, wherein the structural general formula of the extracellular cyclophilin inhibitor of the present invention is as shown in formula (I). According to the present invention, a group capable of reacting with sulfhydryl of cysteine at a specific site on blood albumin is extracted by means of a side chain of a new cyclosporin derivative, and a drug conjugate is rapidly formed after same enters the body, which can effectively restrict the drug to the extracellular area and form targeted inhibition of extracellular cyclophilin, thereby achieving the aim of treating diseases associated therewith.
-
16.发明公开
公开(公告)号：EP4408192A1
公开(公告)日：2024-08-07
申请号：EP22797363.3
申请日：2022-09-30
发明人： YAN, Bing , UFHEIL, Gerhard , WOOSTER, Timothy James , MOCO, Sofia , ZAREI, Amin , KHAZDOOZ, Leila , ENAYATINOOK, Mojtaba , MADARSHAHIAN, Sara , ABBASPOURRAD, Alireza
-
公开(公告)号：EP4335517A3
公开(公告)日：2024-08-07
申请号：EP23212899.1
申请日：2017-07-25
发明人： WISCHIK, Claude Michel , SCHELTER, Björn Olaf , WISCHIK, Damon Jude , STOREY, John Mervyn David
IPC分类号： A61K31/5415 , A61P25/28 , A61P9/10 , A61P25/00 , A61P21/00 , A61P21/04 , A61P25/02 , A61P25/14 , A61P25/16 , A61P43/00 , A61P3/02
CPC分类号： A61K31/5415 , A61P21/00 , A61P21/04 , A61P25/00 , A61P25/02 , A61P25/14 , A61P25/16 , A61P25/28 , A61P3/02 , A61P43/00 , A61P9/10
摘要： The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.
-
-
公开(公告)号：EP4406943A1
公开(公告)日：2024-07-31
申请号：EP22871955.5
申请日：2022-09-20
发明人： XIA, Hongguang , FAN, Mengyang , CEN, Xufeng , XU, Xiaoyan , WU, Ronghai , LIU, Dong , TIAN, Zhen
IPC分类号： C07D305/08 , A61K31/38 , A61P31/04 , A61P9/10
CPC分类号： A61P9/10 , C07D305/08 , A61K31/38 , A61P31/04
摘要： The present application discloses small molecule compounds having a naphthylamine structure and an application thereof. In the present application, the structure of a compound having a structure as shown in general formula (I) is as shown in the drawing. The compound and the pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof that are provided by the present application or the pharmaceutical composition provided by the present application can selectively induce autophagy in damaged mitochondria without affecting or only weakly affecting normal mitochondria, and further have superior metabolic stability and pharmacokinetic properties, lower toxicity, and better druggability.
-
公开(公告)号：EP4405483A2
公开(公告)日：2024-07-31
申请号：EP22873598.1
申请日：2022-09-22
发明人： BRADSHAW, Curt
IPC分类号： C12N15/113 , A61K31/7115 , A61P9/10 , C12N5/10 , C12N15/83
-
-
-
-
-
-
-
-
-
搜索结果
10977 条记录 (耗时 0.023 秒)
